Cantargia Q2 2023: CAN10 Approaching the Clinic - Redeye
Redeye comments on Cantargia’s second quarter report 2023. An application to start a clinical trial with the second project, CAN10, was submitted and approved since our last update.
ANNONS
Redeye comments on Cantargia’s second quarter report 2023. An application to start a clinical trial with the second project, CAN10, was submitted and approved since our last update.